News >

Bipolar Androgen Therapy Effective After Enzalutamide in mCRPC

Jason Harris
Published: Thursday, Jan 11, 2018

Benjamin A. Teply, MD

Benjamin A. Teply, MD
One-third of asymptomatic men with metastatic castration-resistant prostate cancer (mCRPC) who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy (BAT).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x